Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
GV20 Therapeutics
AddedFeb 15, 2024
UpdatedJun 18, 2026
GV20 Therapeutics

GV20 Therapeutics

Series B

GV20 Therapeutics, a US-based firm, uses AI and genomics to discover and develop novel cancer immunology drugs.

HQ
Cambridge, MA, US
Founded
2016
Overview
Compare
Fundraising
Employees
Website

GV20 Therapeutics, founded in Cambridge, United States, is the US branch of GV20 Oncotherapy. The company is dedicated to revolutionizing cancer treatment by leveraging high throughput functional genomics and artificial intelligence to identify novel drug targets in cancer immunology. Their core mission is to discover and develop effective antibody drugs for cancer treatment. GV20's proprietary antibody drug discovery engine is central to their innovative approach, aiming to provide groundbreaking solutions in the oncology market.

Notable affiliated individuals include leading scientists and industry experts in genomics and AI. The company has attracted significant interest from investors focused on cutting-edge biotech innovations. Key achievements include the development of a robust pipeline of promising antibody drug candidates and partnerships with leading research institutions. GV20 Therapeutics has made a substantial impact on the field of cancer treatment by advancing precision medicine and offering new hope for effective cancer therapies.

GV20 Therapeutics - Quick Facts

When was GV20 Therapeutics founded?

GV20 Therapeutics was founded in 2016.

Where is GV20 Therapeutics' headquarters located?

GV20 Therapeutics' headquarters is located in Cambridge, MA, US.

How much has GV20 Therapeutics raised to-date?

As of Oct 14, 2021, GV20 Therapeutics has raised a total of $2.9M (USD).

How many employees does GV20 Therapeutics have?

GV20 Therapeutics has 20 employees as of Feb 5, 2024.

GV20 Therapeutics - Classification

Ownership
  • Venture Capital
Technology
  • AI
  • Biotech
Geographic Exposure
  • United States
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Antibody Drugs
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research
Show 16 more industry codes
NAICS
  • 513200Software Publishers
  • 541500Computer Systems Design and Related Services
  • 510000Information
  • 620000Health Care and Social Assistance
  • 513000Publishing Industries
  • 623000Nursing and Residential Care Facilities
  • 513210Software Publishers
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 8000Health Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 8040Offices And Clinics Of Other Health Practitioners
  • 7371Computer Programming Services
  • 7372Prepackaged Software
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified